Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945310 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL35060 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL9331881 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL13788602 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL450913 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23728804 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21113607 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22515370 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22939675 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL30062304 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| EP-4583928-A2 | RADIONUCLIDE COMPOSITION AND METHOD OF USING SAME FOR DETECTION OF TUMOR CELLS | The Research Foundation for The State University of New York (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025133234-A1 | SORTILIN BINDERS AND BIFUNCTIONAL COMPOUNDS THEREOF | DRAUPNIR BIO APS (DK) | 2025-06-26 | — | — | WO | disclosed |
| CN-120129539-A | Radionuclide composition and method for detecting tumor cells by using radionuclide composition | 纽约州立大学研究基金会 | 2025-06-10 | — | — | CN | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| WO-2024054972-A2 | RADIONUCLIDE COMPOSITION AND METHOD OF USING SAME FOR DETECTION OF TUMOR CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230407391-A1 | Conjugated Polymeric Particle and Method of Making Same | LIFE TECHNOLOGIES CORP (US) | 2023-12-21 | — | — | US | disclosed |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6770259-B2 | ADMINISTEING RADIOLABELED LEUKOTRIENE (LTB4) BINDING AGENT AND A RADIOLABELED PERFUSION IMAGING AGENT; CONCURRENTLY DETECTING THE RADIOLABELED LTB4 BINDING AGENT BOUND AT THE LTB4 RECEPTOR AND THE RADIOLABELED PERFUSION IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
| EP-0999856-B1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | TDP1 4821/4885MAOA 2520/4885MAOB 999/4885 |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | TDP1 4821/4885MAOA 2520/4885MAOB 999/4885 |
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | CBR3, CBR1, NR2E3 | TDP1 4391/4885MAOA 971/4885MAOB 742/4885 |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | TDP1 4815/4885MAOA 3874/4885MAOB 2167/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | TDP1 1918/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | TDP1 4815/4885MAOA 3874/4885MAOB 2167/4885 |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | CCNC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MKI67 | TDP1 2948/4885MAOA 2273/4885MAOB 1827/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | TDP1 258/4885MAOA 1358/4885MAOB 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.